Breast neoplasm
Therapeutic area
Oncology
Rare disease
No
- Definition
- A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Breast neoplasm
- Therapeutic area
- Oncology
- breast neoplasm
- breast neoplasm
- breast neoplasm (disease)
- breast tumor
- breast tumour
- neoplasm of breast
- neoplasm of the breast
- neoplasm, breast
- tumor of breast
- tumor of the breast
- tumour of breast
- tumour of the breast
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0021100
- Parent condition
- MONDO:0002657
Related records
Broader conditions (9)
- Breast disorder
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
Narrower conditions (149)
- Acantholytic variant squamous cell breast carcinoma
- Acinic cell breast carcinoma
- Adenoid cystic breast carcinoma
- Adenoma of nipple
- Adenosquamous breast carcinoma
- Atypical breast papilloma
- Atypical lobular breast hyperplasia
- Basal-like breast carcinoma
- Benign breast adenomyoepithelioma
- Benign breast phyllodes tumor
- Benign ductal tumor of breast
- Benign eccrine breast spiradenoma
- Benign neoplasm of male breast
- Bilateral breast carcinoma
- Breast adenocarcinoma
- Breast adenoma
- Breast adenomyoepithelioma
- Breast angiosarcoma
- Breast apocrine adenoma
- Breast apocrine carcinoma
Trials (13,422)
- 'ADVANCE' (A Pilot Trial)
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
- " Role of Diffusion Weighted Image in the Diagnosis and Follow up of Breast Cancer"
- "Can Do" Versus "Do Do" in Patients With Breast Cancer
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Effectiveness of Community Health Workers in Breast Cancer Prevention in Jumla: a Cluster Randomized Trials
- "Electro Acupuncture in the Treatment and Management of Chemotherapy Induced Peripheral Neuropathy"
- "Impact of Chemotherapy-induced Alopecia on the Quality of Life of Women With Breast Cancer"
- "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot Study to Assess the Value of Written Information Documents.
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- "Serratus Anterior Plane Block" Versus "Serratus Posterior Superior Plane Intercostal Plane Block" for Patients Undergoing Breast Surgery
- "Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients"
- "The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial"
- (Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- [18F] F-GLN by PET/CT in Breast Cancer
- [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer
Approved drugs (39)
- Abemaciclib
- Alpelisib
- Anastrozole
- Atezolizumab
- Bevacizumab
- Capecitabine
- Capivasertib
- Cyclophosphamide
- Denosumab
- Docetaxel
- Docetaxel anhydrous
- Doxorubicin hydrochloride
- Elacestrant hydrochloride
- Epirubicin hydrochloride
- Eribulin mesylate
- Estradiol
- Estrogens, conjugated
- Everolimus
- Exemestane
- Fulvestrant
Drugs in development (198)
- Afatinib Phase 3
- AFP-464 Phase 2
- Agatolimod sodium Phase 2
- Aldesleukin Phase 3
- Alendronic acid Phase 1
- Alisertib Phase 2
- Amcenestrant Phase 3
- Anvatabart opadotin Phase 2
- Arzoxifene Phase 3
- Aspirin Phase 3
- Atamestane Phase 3
- Atorvastatin Phase 3
- Avelumab Phase 3
- Axitinib Phase 1
- Azacitidine Phase 2
- Bicalutamide Phase 3
- Bintrafusp alfa Phase 2
- Bivatuzumab Phase 1
- Boserolimab Phase 1
- Buparlisib Phase 3
Other linked drugs (8)
- Cefazolin
- Clindamycin
- Elinzanetant
- Eribulin
- Etirinotecan pegol
- Ibandronic acid
- Mitoquinone cation
- Verteporfin